ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near New York, NY, USA:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

New York, New York, United States and 7 other locations

radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are be...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Radiation: External-beam radiotherapy (XRT)
Biological: SIRPant-M

Phase 1

SIRPant Immunotherapeutics

Hackensack, New Jersey, United States and 2 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Drug: CC-99282
Drug: Tafasitamab

Phase 1, Phase 2

Celgene
Celgene

Hackensack, New Jersey, United States and 88 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

New York, New York, United States and 73 other locations

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

New York, New York, United States and 26 other locations

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Hackensack, New Jersey, United States and 66 other locations

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting
Lymphoma,Non-Hodgkin
Drug: Placebo
Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer
Bayer

New York, New York, United States and 188 other locations

administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...

Enrolling
Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: CFT7455

Phase 1, Phase 2

C4 Therapeutics

New York, New York, United States and 12 other locations

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Ho ...

Enrolling
Follicular Lymphoma
Lymphoma, Non-Hodgkin
Drug: Tazemetostat
Drug: Venetoclax

Phase 1

Weill Cornell Medicine (WCM)
Weill Cornell Medicine (WCM)

New York, New York, United States

Locations recently updated

1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patients with B-Cell non...

Enrolling
Non Hodgkin Lymphoma
Drug: IPH6501

Phase 1, Phase 2

Innate Pharma

New York, New York, United States and 8 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems